At the recent ACHEMA trade show in Frankfurt, Germany, GEA, a world-class supplier of equipment and technology to a wide range of industrial process industries, and Bangladesh-based Healthcare Pharmaceuticals Limited (HPL), a manufacturer of branded generic products for markets in Asia, Africa, Europe and the CIS region, shook hands on a €4 million deal to deliver a fully contained “one-stop-shop” solution for potent oral solid dosage form production.
HPL CEO, Muhammed Halimuzzaman, commented: “By implementing GEA’s proven manufacturing solutions and innovations, we intend to establish ourselves as a global supplier and operate on a worldwide platform. We see GEA as a quality provider of the latest technological advances and by investing in best-in-class equipment, we can maximize our R&D efforts and capitalize on the very worthwhile expenditure by getting first-rate products to market quicker.”
HPL also appreciated that, although GEA operates worldwide, the company also has a strong regional presence, thereby ensuring close proximity and support. Additionally, by partnering with a like-minded “innovative organization” such as GEA, they hope to become a globally recognized supplier of high quality products.
The process equipment provided by GEA includes a fully integrated and contained (OEB 5) 800 L granulation line for hormone-based products with an STTWA of 1–10 µg/m3. The end-to-end solution provides API dispensing through high containment valves to the contained loading of a GEA tablet press. Both wet granulation and direct compression tablet production can be accommodated.
Navin Lakhanpaul, GEA’s VP Sales & Marketing, Pharma, stated: “I am delighted that HPL is buying from GEA. We are a world-leading supplier of innovative technology driven solutions and this recent agreement further consolidates our long-term and loyal partnership.”
“The level of trust and our collaborative approach to business has won repeat trade from HPL, built on previous projects, and taken our commercial relationship and partnership to the next level,” Marcus Michel, GEA’s Executive VP APC Pharma, added. GEA and HPL first collaborated in 2013 with the delivery of an integrated PharmaConnect system for the research and development of highly potent “cytotoxic” applications.
Halimuzzaman concluded by noting: “Our collaborative partnership with GEA has been invaluable. Guided by their expertise, experience and know-how, HPL has implemented state-of-the-art production equipment that will optimize our manufacturing processes and enable us to deliver world-class products that are safe, high quality and efficacious.”
Contact: Raman Singh – Pharma Sales
Raman.Singh@gea.com Tel: +91 9687614613